Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

NCT04428944 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation of drivers (PVAI+drivers) 3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.

Conditions Studied

Interventions

  • PROCEDURE Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)
  • PROCEDURE Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)
  • PROCEDURE Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)

Study Locations (20)

Other

  • Royal Adelaide Hospital and Cardiovascular Centre — Adelaide
  • Alfred Health — Melbourne
  • Royal Melbourne Hospital — Parkville
  • Medical University of Graz — Graz
  • Ordensklinikum Linz GmbH — Linz
  • OLV Hospital Aalst — Aalst
  • Antwerp University Hospital (UZA) — Edegem
  • AZ Sint-Jan — Ruddershove

British Colombia

  • Vancouver General Hospital — Vancouver
  • St. Paul's Hospital, Vancouver, BC — Vancouver
  • Royal Jubilee Hospital — Victoria

Quebec

  • MUHC, McGill University Health Centre — Montreal
  • University of Ottawa Heart Institute — Ottawa
  • Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) — Québec

Ontario

  • Hamilton General Hospital — Hamilton
  • Southlake Regional Health Center — Newmarket

Massachusetts

  • Brigham & Women'S Hosptial Inc. — Boston

Australian Capital Territory

  • Canberra Heart Rhythm Foundation — Garran

Alberta

  • University of Calgary Foothills — Calgary

QC - Québec

  • Laurent Macle — Montreal

Trial Details

FieldValue
Enrollment Target 617 participants
Start Date 2021-06-01
Est. Completion 2027-12
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04428944

The ClinicalTrials.gov registry entry for NCT04428944 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions — of which Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04428944 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, British Colombia, Quebec. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04428944 about?

NCT04428944 is a clinical study titled "STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation". The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation of drivers (PVAI+drivers) 3. PV antral isolation plus isolation of posterior wall (PVAI+box) All thr...

What is the current status of trial NCT04428944?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 617 participants. The study started on 2021-06-01. Estimated completion is 2027-12.

What conditions does trial NCT04428944 study?

This clinical trial studies the following conditions: Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04428944?

The interventions under investigation include: Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI) (PROCEDURE), Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers) (PROCEDURE), Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box) (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04428944?

This trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04428944 being conducted?

This trial has 20 study locations across Massachusetts, Australian Capital Territory, Alberta, British Colombia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial